Actylis, a global manufacturer and sourcing expert of critical raw materials and performance ingredients, is a leader in the life science industry. The company’s hybrid business model combines manufacturing and sourcing, providing unparalleled choice and flexibility to customers in high-growth end markets. Actylis’ CEO, Gilles Cottier, discusses the importance of supply chain risk assessment, supplier diversification, and geographical diversification for manufacturers. He also shares Actylis’ commitment to investing in facilities and capabilities, ensuring the company is at the cutting edge of manufacturing processes and regulatory compliance. Actylis provides finished drug manufacturers in biopharma and pharma, as well as manufacturers in the cosmetics, nutrition, specialty chemicals, and agriculture markets, with the best supply solution for their needs. The company’s ongoing commitment to innovation, flexibility, and customer choice positions it as a leader in the life science industry, and its vision for growth and success includes organic growth and more acquisitions in the life science sector.
A New Global Enterprise: Actylis
Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, was established in September 2022 after the transformation of US-based fine and specialty chemicals distributor, Aceto. Gilles Cottier, the CEO of Actylis, recently spoke with Ralf Kempf and Michael Reubold to discuss the creation of the new brand identity, the challenges of combining multiple companies, and Actylis’ strategy going forward.
Actylis represents the consolidation of eleven industry specialists (A&C, A&C Bio Buffer, Aceto, Biotron Laboratories, Cascade Chemistry, Finar, Inter-Actifs, IsleChem, Pharma Waldhof, Syntor Fine Chemicals, and Talus) into an integrated global ingredient powerhouse. The name ‘Actylis’ was derived from the Latin terms for ‘act’ and ‘life’, reflecting the company’s aim to unite a wide range of capabilities of several manufacturing and sourcing specialists for the life science industry into a unique global enterprise with a hybrid approach.
Actylis combines production, sales, and R&D capacities in a new business model that enables the company to provide highly flexible and customized solutions that address specific needs while ensuring reliable on-time delivery of high-quality ingredients essential to customers’ success. The synergies between the individual companies that formed Actylis created a company that offers key benefits to customers in high-growth end markets.
While each of the companies that formed Actylis was well known and trusted in their individual fields, the legacy brands, especially the Aceto brand, represented something significantly different than what they had been in the past. The consolidation of these companies meant that they had transformed into something different and improved over what they had been previously. Actylis now has global R&D centers of excellence, GMP and Non-GMP manufacturing plants in various locations in North America, Europe, and Asia, sourcing hubs at strategic locations, as well as global supply chain, technical sales, and quality teams.
The introduction of the new brand identity makes the process of sales synergies between the integrated companies much easier and more cost-effective. Actylis provides customers with the benefits of multiple industry specialists, united under one new brand that represents a unique global enterprise with a hybrid approach.
Actylis’ Approach to Innovation and Flexibility in the Life Science Industry
In a recent interview with CHEManager, Gilles Cottier, the CEO of Actylis, discussed the company’s approach to innovation and flexibility in the life science industry. Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients, was created in September 2022 from US-based fine and specialty chemicals distributor Aceto.
Actylis serves finished drug manufacturers in biopharma and pharma, as well as manufacturers in the cosmetics, nutrition, specialty chemicals, and agriculture markets. The company’s R&D Centers of Excellence work closely with customers to develop novel and niche ingredients, enabling them to commercialize their finished drug products more rapidly.
The company’s hybrid business model, which combines manufacturing and sourcing, allows Actylis to offer unparalleled choice and flexibility to its customers. By embracing choice, Actylis can provide a standard product sourced from anywhere in the world, manufacture a product at one of its facilities, or create a product specifically designed to suit the needs of its customer. This gives customers flexible options surrounding supply chain, geography, innovation, timeline, and cost.
According to Cottier, the industry Actylis serves is a global leader of innovative technology adoption, such as targeted therapies and gene and cell therapies. As a raw material supplier, Actylis needs to be flexible and agile to create customized critical raw materials to serve this innovative market. This consultative approach to customer relationships enables Actylis to provide customers with the difference they need to support innovation and growth.
Actylis’ strategy is based on the current market trend in the life science sector, the need for more flexibility and agility in raw material manufacturing and supply. The company’s intimate knowledge of customers’ needs, consultative perspective, and focus on innovation and quality provide benefits to customers in high-growth end markets. By providing flexible solutions, Actylis can address the most pressing needs and requirements of its customers, such as a move towards more local supply to mitigate risk, a reversal of raw material supplier consolidation to friend-shoring and supply diversity, an even greater focus on sustainability, and a reduction of focus on lean models, replaced by smarter inventory planning approaches and supplier diversity.
Actylis’ global presence allows it to offer customers great geographic flexibility. The company’s ability to offer on-, re-, or nearshoring is in line with the growing demand for these options in the markets it serves.
Actylis’ Vision for Growth and Success in the Life Science Industry
In a recent interview with CHEManager, Gilles Cottier, the CEO of Actylis, discussed the company’s vision for growth and success in the life science industry. Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients, provides key benefits to customers in high-growth end markets such as finished drug manufacturers in biopharma and pharma, as well as manufacturers in the cosmetics, nutrition, specialty chemicals, and agriculture markets.
According to Cottier, supply chain risk assessment is likely to be a priority for manufacturers over the next 2 – 3 years. Once this assessment has been completed, supplier diversification will be at or near the top of most risk mitigation strategies. Geographical diversification is the likely second stage, with near and “ally” shoring being the preferred approach. Onshoring will be the slowest to implement as costs, regulations, and available resources will take time to work through. Actylis’ global network and local regulatory expertise give the company the flexibility to deliver the best supply solution for its customers’ needs.
Actylis regularly reviews global and local technological advances and legislative & regulatory changes to ensure it is at the cutting edge. The company benchmarks itself against the best companies in its and other markets to ensure it is aware of and strives for the most up-to-date systems and practices to use across its network of facilities. Actylis has an ongoing commitment to investing in its facilities, with the opening of a new 30,000 ft2 state-of-the-art clinical cGMP API manufacturing facility in Eugene (OR) and the recent upgrade of its two GMP facilities in Montreal to Class 7 & 8.
Actylis’ strategy is simple: provide customers with choice. The company’s hybrid business model, which combines manufacturing and sourcing, allows Actylis to offer unparalleled choice and flexibility to its customers. The company will continue to mature this strategy via organic growth and more acquisitions in the life science sector over the coming years.
Actylis is the culmination of an ambitious initiative launched several years ago to address the major unmet need for better and more dependable access to critical raw materials and performance ingredients essential for the manufacture of highly regulated products in key industries. The supply chain challenges of the past few years have made Actylis’ vision especially relevant, and the company is proud to help its customers dependably manufacture the life-giving products we all rely on.
Actylis’ commitment to innovation, flexibility, and customer choice positions the company as a leader in the life science industry. Its global presence and local regulatory expertise give it the flexibility to deliver the best supply solution for its customers’ needs, and its ongoing investment in facilities and capabilities ensures it is at the cutting edge of manufacturing processes and regulatory compliance.
Don’t miss interesting posts on Famousbio
